Wire · opportunities
Edesa Biotech receives FDA clearance for vitiligo study expansion
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 16 October 2026 · Fusion42 review
Edesa Biotech has received FDA clearance for expanding its Phase 2 clinical study of EB06 in vitiligo to include patient recruitment in the United States, with topline data expected in late 2027. EB06 is a monoclonal antibody targeting CXCL10, being tested as one of the first systemic drug therapies for vitiligo, a chronic autoimmune disease with no current approved systemic treatments in the US.
This Wire brief sits within Fusion42's coverage of Biotech, and 6 sources have reported it between 15 Oct 2026 and 16 Oct 2026.
◆ ◆ The Wire takeaway
You can now enter the US market with a systemic vitiligo drug candidate; the regulatory gate is open for patient enrolment which can boost trial speed and credibility. Acting on US recruitment and trial site strategy this quarter could set your drug development on a faster path to a major market breakthrough.
◆ Coverage
6 sources · first reported 15 Oct 2026 · latest 16 Oct 2026
◆ Related on Wire
◆ Topics